ALAD

Across TCGA pan-cancer cohorts, ALAD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALAD data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALAD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALAD expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ALAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.938	0.739	.001	41	view →
PDAC	DFS	Median	All	0.829	0.698	.011	9	view →
LUAD	DFS	Quartile	III,IV	0.367	0.947	.006	7	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALAD–CCRCC (OS)

Open the CCRCC breakdown →